Format

Send to

Choose Destination
Blood Purif. 2017;44(3):193-197. doi: 10.1159/000475982. Epub 2017 Jun 10.

Novel Insights into the Direct Removal of Endotoxin by Polymyxin B Hemoperfusion.

Author information

1
Division of Biochemistry and Keenan Research Centre for Biomedical Science, St. Michael's Hospital, University of Toronto, Toronto, Canada.

Erratum in

Abstract

AIM:

To demonstrate the capacity of polymyxin B-direct hemoperfusion (PMX-DHP) column Toraymyxin® 20R (PMX-20R) in removing endotoxin (LPS) from perfused blood, serum and plasma.

METHODS:

Endotoxin-spiked bovine serum was perfused in PMX-20R as per the recommended performance testing protocol. Samples were taken at various time points to assess the amount of endotoxin removed during a 4-h session. In another set of experiments, FITC-labelled LPS (FITC-LPS) was spiked into a pool of human whole blood, followed by perfusion with the spiked blood for 2 h in order to allow FITC-LPS to bind PMX-20R. The amount of LPS was extracted from the columns and the amount of specifically bound LPS was determined by fluorometry.

RESULTS:

PMX-20R columns perfused with bovine serum had an average binding rate of 88%, equivalent to approximately 12 µg of LPS. When PMX-20R was perfused with human whole blood, the columns bound an average of 20 µg of FITC-LPS.

CONCLUSION:

PMX-20R can bind LPS in all the biological fluids tested. The calculated binding capacity of 12-20 µg LPS suggests that in septic cases where endotoxin is present in the circulation, PMX-20R is able to adsorb clinically significant levels of endotoxin.

KEYWORDS:

Endotoxin activity assay; Hemoperfusion; LPS/endotoxin adsorption; Polymyxin B-direct hemoperfusion; Sepsis; Toraymyxin® 20R

PMID:
28601867
DOI:
10.1159/000475982
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland
Loading ...
Support Center